Vaccine candidates derived from a novel infectious cDNA clone of an American genotype dengue virus type 2 - Wikidata - wikimedia - TriplyDB

Vaccine candidates derived from a novel infectious cDNA clone of an American genotype dengue virus type 2

Vaccine candidates derived from a novel infectious cDNA clone of an American genotype dengue virus type 2

http://www.wikidata.org/entity/Q24805308

about

Functions of the 3' and 5' genome RNA regions of members of the genus Flavivirus Recombinant, live-attenuated tetravalent dengue virus vaccine formulations induce a balanced, broad, and protective neutralizing antibody response against each of the four serotypes in rhesus monkeys.Dengue Fever in Humanized NOD/SCID Mice A tick-borne Langat virus mutant that is temperature sensitive and host range restricted in neuroblastoma cells and lacks neuroinvasiveness for immunodeficient mice Vaccine candidates for dengue virus type 1 (DEN1) generated by replacement of the structural genes of rDEN4 and rDEN4Delta30 with those of DEN1 Dengue virus type 3 vaccine candidates generated by introduction of deletions in the 3′ untranslated region (3′-UTR) or by exchange of the DENV-3 3′-UTR with that of DENV-4 Primary and Secondary Infections of Macaca fascicularis Monkeys with Asian and American Genotypes of Dengue Virus 2 A Tetravalent Dengue Vaccine Based on a Complex Adenovirus Vector Provides Significant Protection in Rhesus Monkeys against All Four Serotypes of Dengue Virus Patterns of cellular immunity associated with experimental infection with rDEN2Δ30 (Tonga/74) supports its suitability as a human DENV challenge strain IRAV (FLJ11286), an Interferon Stimulated Gene with Antiviral Activity Against Dengue Virus, Interacts with MOV10 Issues related to recent dengue vaccine development.The 5' and 3' Untranslated Regions of the Flaviviral Genome.Current progress in dengue vaccines The Role of Heterotypic DENV-specific CD8+T Lymphocytes in an Immunocompetent Mouse Model of Secondary Dengue Virus Infection.Bioinformatics in new generation flavivirus vaccines.RNA virus reverse genetics and vaccine design.Genetic and phenotypic characterization of sylvatic dengue virus type 4 strains Dengue vaccines: state of the art.Development and characterization of a reverse genetic system for studying dengue virus serotype 3 strain variation and neutralization.Dengue vaccines: recent developments, ongoing challenges and current candidates.Novel benzoxazole inhibitor of dengue virus replication that targets the NS3 helicase.Successful propagation of flavivirus infectious cDNAs by a novel method to reduce the cryptic bacterial promoter activity of virus genomes.Natural attenuation of dengue virus type-2 after a series of island outbreaks: a retrospective phylogenetic study of events in the South Pacific three decades ago.Development and clinical evaluation of multiple investigational monovalent DENV vaccines to identify components for inclusion in a live attenuated tetravalent DENV vaccine Dual miRNA targeting restricts host range and attenuates neurovirulence of flaviviruses.Full-length infectious clone of a low passage dengue virus serotype 2 from Brazil Targeted mutagenesis as a rational approach to dengue virus vaccine development.Temperature-dependent production of pseudoinfectious dengue reporter virus particles by complementation.A novel inhibitor of dengue virus replication that targets the capsid protein Nucleolin interacts with the dengue virus capsid protein and plays a role in formation of infectious virus particles.Recent progress in dengue vaccine development.Dengue epidemiology and pathogenesis: images of the future viewed through a mirror of the past.The live attenuated dengue vaccine TV003 elicits complete protection against dengue in a human challenge model.

P2860

Q26700111-F5BD024E-DF7B-44DC-AA78-DB72201684BC Q27469474-C3B4F872-BADD-41A8-A7A7-1F089055E99D Q27472676-3D347E73-EDE6-43C7-9F03-7C2FC3FC8E39 Q27472824-F79D781A-7F15-4C76-8106-E0E0D72F430D Q27478162-E95EBB20-8DF4-442D-8B4E-3ACEC36BE5EF Q27485404-AC772495-3D58-4D00-A79C-FDA70D7B19A3 Q27485489-F9789A2A-AAC8-4AD0-8622-5DD67D757E0D Q27486406-4F9D0897-3E52-4B37-88A0-9055C62D3F8C Q28729784-84025687-C7D0-4D12-A762-E81018732D21 Q28733416-6D4A968A-CE6B-44CF-8C92-9B63CC614C7E Q30395396-97B7E3C9-CC71-4B10-A9B2-BBE10DBB8B2A Q32183359-34447FFA-BAF9-4B96-9968-E6F57E6EDE5D Q33408300-A89175E4-7CDC-4759-A01C-A543652EAC49 Q33817714-9AB19F29-96F3-4860-AF90-A7C8DF61E09E Q33839001-06F231F2-E916-4272-91AB-EADA0BB6C643 Q33963398-CEFCBCE4-577C-4113-B50D-A12CA48B6613 Q34104330-B465CCCB-D02F-4E66-9CF3-51503C5FCC9F Q34109652-BF1D8DD6-FD87-459F-A35E-4D246818DA6B Q34184711-90BECA28-28A3-4400-B787-E9CAB1C0F91D Q34367194-F37ED78D-AC06-4455-81CA-E5FA0AAE4D7E Q34583461-AF12D93E-29FE-40D0-9F30-05E600AE7EE8 Q34742978-73279561-9C7C-4881-938F-FEA2EE0C13CA Q35147237-825BD44B-FED0-41FD-A668-9F1443C4161E Q35206695-69AF4340-B9E7-46B6-BA61-3021F8935B08 Q35532741-7B960484-DBB4-4577-97E5-9423C6D495D4 Q36059707-A097CF26-6133-4015-A4FC-3BE9D9B9DE2F Q36118259-F9BA02F7-F571-4819-ABDC-5AA7A7EFF12E Q36192685-B071CA5F-AC8C-476A-BE77-178D585F2AFE Q36505563-2A993DB1-887F-413D-824B-6D37CEF0A7EE Q37336680-901CA869-649A-4974-ACB8-0404B07F7F5D Q38303232-412237A2-B4A4-4036-B930-E33A1397F4DD Q38614539-7BBA63B6-AA1B-4BA6-80C5-6DE2D4630DF9 Q40109446-25236327-48EC-4BA3-A738-EDBDAACEE59F

P2860

Vaccine candidates derived from a novel infectious cDNA clone of an American genotype dengue virus type 2

http://www.wikidata.org/entity/Q24805308

description

2004 nî lūn-bûn

@nan

2004 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2004 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

name

Vaccine candidates derived fro ...... n genotype dengue virus type 2

@ast

Vaccine candidates derived fro ...... n genotype dengue virus type 2

@en

Vaccine candidates derived fro ...... n genotype dengue virus type 2

@nl

type

label

Vaccine candidates derived fro ...... n genotype dengue virus type 2

@ast

Vaccine candidates derived fro ...... n genotype dengue virus type 2

@en

Vaccine candidates derived fro ...... n genotype dengue virus type 2

@nl

prefLabel

Vaccine candidates derived fro ...... n genotype dengue virus type 2

@ast

Vaccine candidates derived fro ...... n genotype dengue virus type 2

@en

Vaccine candidates derived fro ...... n genotype dengue virus type 2

@nl

P1433

Q24805308-CC45405A-253C-438B-8D80-7CDDBBBC98FF

P1476

Q24805308-61960096-B65E-4869-97E6-3840A02C2DD1

P2093

Q24805308-5B7CD12D-0DA1-4B29-9694-DCA940B19E11

Q24805308-C817BCD3-256E-405C-A410-EA15D3A77589

Q24805308-FF842192-948B-4330-88FC-DFF536F018AE

P2860

Q24805308-0DB40A70-33A3-4A30-A2A2-EDFF8621F688

Q24805308-0DD4466F-00F5-4E8F-AEFB-E3CF736049F6

Q24805308-129725C2-9BBF-4170-9D24-E0DC52C54FF1

Q24805308-21C4E4D2-1FF0-4DDA-97F1-36E074296243

Q24805308-268F831C-8F97-43C1-A296-F4FFE5362638

Q24805308-2D2DD57D-2688-49AE-9EB1-8B506DD76DD4

Q24805308-308AA638-DF01-4015-921B-373149946E81

Q24805308-49F310B3-9E3D-4EF9-9898-9AF93AF9B7E2

Q24805308-4B1CCA17-E7B6-4662-A870-76A3D6DCEF22

Q24805308-4E6CF95D-59C6-42D2-976F-F8809708AC63

P2888

Q24805308-B86A85CE-F001-4DCF-B016-B4A71F95A4E0

P304

Q24805308-9DC0131C-A685-4B02-8932-FFC08ECC4B25

P31

Q24805308-58DB5005-7FED-4AA4-AB2B-D9841FBFD8E4

P356

Q24805308-0E04877F-61D2-4256-8380-AA19EE2AF5DC

P407

Q24805308-AB96E69D-5C8B-4D1F-A7E2-492B7F31E3C0

P433

Q24805308-EC70A92B-6AF8-458C-A4AB-A23B353857A4

P478

Q24805308-83C05F40-5EE6-4FE2-BECD-363360471DBA

P50

Q24805308-0D982921-DC67-496C-B994-5B20F92BB493

Q24805308-70216C2E-D472-4075-9B9B-24A029F42946

P577

Q24805308-CB305201-3CEE-4F81-831D-3A8039EE9CC8

P5875

Q24805308-C3172127-4380-4860-91DD-DBDFEE865059

P6179

Q24805308-4061E7DD-50C1-49E6-8299-5F459D17A2E2

P698

Q24805308-9F107695-FA85-48A6-B2EF-6CA69E8DBA34

P921

Q24805308-91F1194F-CF78-45C7-8F53-629DD29B4EA3

P932

Q24805308-F6DA314A-BDAF-4952-8F22-B03893FC1CD8

P356

P1433

BMC Infectious Diseases

P1476

Vaccine candidates derived fro ...... n genotype dengue virus type 2

@en

P2093

Brian R Murphy

http://www.w3.org/2001/XMLSchema#string

Christopher T Hanson

http://www.w3.org/2001/XMLSchema#string

Joseph E Blaney

http://www.w3.org/2001/XMLSchema#string

P2860

Dengue and dengue hemorrhagic fever

Dengue virus structural differences that correlate with pathogenesis.

Chemical mutagenesis of dengue virus type 4 yields mutant viruses which are temperature sensitive in vero cells or human liver cells and attenuated in mice.

Derivation and characterization of a dengue type 1 host range-restricted mutant virus that is attenuated and highly immunogenic in monkeys.

A Live, Attenuated Dengue Virus Type 1 Vaccine Candidate with a 30-Nucleotide Deletion in the 3' Untranslated Region Is Highly Attenuated and Immunogenic in Monkeys

American Genotype Structures Decrease Dengue Virus Output from Human Monocytes and Dendritic Cells

Dengue 2 PDK-53 Virus as a Chimeric Carrier for Tetravalent Dengue Vaccine Development

Dengue/Dengue Hemorrhagic Fever: The Emergence of a Global Health Problem

Origins of dengue type 2 viruses associated with increased pathogenicity in the Americas

Genetically modified, live attenuated dengue virus type 3 vaccine candidates.

P2888

P304

39

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1471-2334-4-39

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

4

http://www.w3.org/2001/XMLSchema#string

P50

Kathryn A. Hanley

Stephen S Whitehead

P577

2004-10-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8253368

http://www.w3.org/2001/XMLSchema#string

P6179

1011407391

http://www.w3.org/2001/XMLSchema#string

P698

15461822

http://www.w3.org/2001/XMLSchema#string

P921

P932

524489

http://www.w3.org/2001/XMLSchema#string